# A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma

> **NCT03802071** · PHASE1,PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 44 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Durvalumab+doxorubicin cobination

## Key facts

- **NCT ID:** NCT03802071
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-16
- **Primary completion:** 2022-08-10
- **Final completion:** 2022-08-10
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03802071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03802071, "A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03802071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*